Bronchopulmonary Dysplasia: Challenges and Advances

A special issue of Children (ISSN 2227-9067).

Deadline for manuscript submissions: 1 April 2025 | Viewed by 2450

Special Issue Editor


E-Mail Website
Guest Editor
Division of Neonatology, Department of Pediatrics, The Children’s Regional Hospital at Cooper/Cooper Medical School of Rowan University, Camden, NJ 08103, USA
Interests: bronchopulmonary dysplasia; non-invasive ventilation; lung development; lung injury; neonatal sepsis

Special Issue Information

Dear Colleagues,

Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in infants. This condition occurs in preterm neonates with immature lungs due to genetic-environmental interactions. The environmental factors that contribute to the etiopathogenesis of BPD include exposure of the immature lung to sepsis (can be antenatal, i.e., chorioamnionitis, or postnatal, which can be locally in the lung or systemic), hyperoxia, and invasive ventilation, among other factors (e.g., for fluid and nutritional factors). There are several challenges to the diagnosis of BPD. In addition, understanding the pathogenesis, pathology, clinical dilemmas, management strategies, complications, and pulmonary and neurodevelopmental outcomes are still being investigated and optimized. We invite clinical/translational original research manuscripts as well as review articles addressing the specific areas about BPD, as noted above. Manuscripts discussing the controversies in the diagnostic criteria, utility of biomarkers, therapeutic approaches (e.g., for ventilation – both invasive and non-invasive strategies, drug therapies), complications (e.g. for BPD-associated pulmonary hypertension), and long-term issues post-NICU discharge are a few of the areas that will be considered appropriate for this Special Issue. Authors are encouraged to contact me directly (bhandari-vineet@cooperhealth.edu) if they wish to discuss the specific area their article would focus on, prior to submission.

Prof. Vineet Bhandari
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bronchopulmonary dysplasia
  • chronic lung disease
  • epidemiology
  • drug therapy
  • nutrition
  • invasive ventilation
  • non-invasive ventilation
  • biomarkers
  • surfactant
  • hyperoxia
  • lung injury

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 819 KiB  
Article
Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators—The Pediatric Cardiologist Point of View
by Anna Migdał, Anna Sądel-Wieczorek, Edyta Ryciak, Alicja Mirecka-Rola, Grażyna Brzezińska-Rajszys and Małgorzata Żuk
Children 2021, 8(5), 326; https://doi.org/10.3390/children8050326 - 22 Apr 2021
Cited by 3 | Viewed by 1890
Abstract
Pulmonary hypertension in children with bronchopulmonary dysplasia (BPD-PH) significantly worsens the prognosis. Pulmonary vasodilators are often used in BPD-PH but the short-term outcome of treatment is not well described. The aim of this study was to evaluate BPD-PH children diagnosed beyond 36 weeks [...] Read more.
Pulmonary hypertension in children with bronchopulmonary dysplasia (BPD-PH) significantly worsens the prognosis. Pulmonary vasodilators are often used in BPD-PH but the short-term outcome of treatment is not well described. The aim of this study was to evaluate BPD-PH children diagnosed beyond 36 weeks postmenstrual age treated with pulmonary vasodilators (sildenafil, bosentan, or both) and to assess the short and long-term effect of oral pulmonary vasodilators treatment. Twenty patients were included in the study. Cardiology evaluation (WHO-FC, NTproBNP, oxygen saturation, pulmonary to systemic pressure ratio PAP/SAP) was performed at diagnosis and after treatment initiation. In the majority of patients improvement in all evaluated factors was observed. No side effects of vasodilators were observed. PH resolved in 10 patients after a mean of 21.4 months of treatment. Six patients died. The number of poor prognostic factors commonly used to assess patients with pulmonary arterial hypertension (PAH) decreased significantly during BPD-PH treatment. The influence of BPD-PH perinatal risk factors on prognosis was considered but was not confirmed. In conclusion, the treatment of BPD-PH with pulmonary vasodilators was well tolerated and led to a clinical improvement with the possibility of discontinuation without recurrence of PH. Prognostic factors used in pediatric PAH risk stratification also seem to be useful in assessing treatment efficacy and prognosis in patients with BPD-PH. Full article
(This article belongs to the Special Issue Bronchopulmonary Dysplasia: Challenges and Advances)
Show Figures

Figure 1

Back to TopTop